Candace Holstein, NP
Primary Care · Orangeburg, SCNPI 1659046878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $486 and has fallen 81.6% since, to $90 in 2024.
Across 63 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$204
- Lilly USA, LLC$178
- Novo Nordisk$170
- Abbott$89
- Boehringer Ingelheim$64
- Xeris Pharmaceuticals, Inc.$49
- plus $280 from 10 others
What the payments were for
- Food & beverage$98495%
- Other$505%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $204 |
| Lilly USA, LLC | 10 | $178 |
| Novo Nordisk | 8 | $170 |
| Abbott | 3 | $89 |
| Boehringer Ingelheim | 3 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Neurocrine Biosciences, Inc. | 3 | $47 |
| Sanofi | 1 | $40 |
| Pfizer | 2 | $35 |
| AstraZeneca | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| GSK | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Bayer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$1,034 in reported general payments places this provider in the 60th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $85,026 |
| JardianceEmpagliflozin | 108 | $81,051 |
| MounjaroTirzepatide | 52 | $62,634 |
| EliquisApixaban | 79 | $52,571 |
| Repatha SureclickEvolocumab | 34 | $40,493 |
| FarxigaDapagliflozin Propanediol | 46 | $35,220 |
| JanuviaSitagliptin Phosphate | 33 | $29,759 |
| TrulicityDulaglutide | 22 | $25,460 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $24,538 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,759 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,388 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,841 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $5,987 |
| MyrbetriqMirabegron | 11 | $4,992 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $64 | $88,439123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $178 | $88,09374 claims |
| Novo NordiskOzempic | $170 | $85,02673 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $35 | $65,745109 claims |
| PfizerEliquis | $35 | $52,57179 claims |
| GSKTrelegy Ellipta | $21 | $18,75924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 115 primary care providers in South Carolina.
Other primary care in Orangeburg
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
- Heather MartinSeneca$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.